These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11279947)

  • 21. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia.
    Arnold LM; Hess EV; Hudson JI; Welge JA; Berno SE; Keck PE
    Am J Med; 2002 Feb; 112(3):191-7. PubMed ID: 11893345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review.
    Taylor AP; Adelman JU; Freeman MC
    Headache; 2007 Sep; 47(8):1200-3. PubMed ID: 17883526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG).
    Bayer O; Adrion C; Al Tawil A; Mansmann U; Strupp M;
    Trials; 2019 Dec; 20(1):813. PubMed ID: 31888723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
    Cady RK; Mathew N; Diener HC; Hu P; Haas M; Novak GP;
    Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
    Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term migraine prevention with topiramate: open-label extension of pivotal trials.
    Rapoport A; Mauskop A; Diener HC; Schwalen S; Pfeil J
    Headache; 2006; 46(7):1151-60. PubMed ID: 16866719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
    Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
    Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial.
    Winner P; Pearlman EM; Linder SL; Jordan DM; Fisher AC; Hulihan J;
    Headache; 2005; 45(10):1304-12. PubMed ID: 16324162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.
    Gross E; Putananickal N; Orsini AL; Schmidt S; Vogt DR; Cichon S; Sandor P; Fischer D
    Trials; 2019 Jan; 20(1):61. PubMed ID: 30654835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
    Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Sun H; Dodick DW; Silberstein S; Goadsby PJ; Reuter U; Ashina M; Saper J; Cady R; Chon Y; Dietrich J; Lenz R
    Lancet Neurol; 2016 Apr; 15(4):382-90. PubMed ID: 26879279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
    Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
    JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study.
    Suvanto-Luukkonen E; Koivunen R; Sundström H; Bloigu R; Karjalainen E; Häivä-Mällinen L; Tapanainen JS
    Menopause; 2005; 12(1):18-26. PubMed ID: 15668596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.
    Kobak KA; Greist JH; Jefferson JW; Katzelnick DJ
    J Clin Psychopharmacol; 2002 Jun; 22(3):257-62. PubMed ID: 12006895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.